Is IV tissue plasminogen activator beneficial in patients with hyperdense artery sign?
Abstract
Objective: To evaluate the effect of IV recombinant tissue plasminogen activator (rt-PA) in patients with hyperdense artery sign (HAS) on initial CT scan.
Methods: The authors determined the differential effect of IV rt-PA (0.9 mg/kg) in patients with HAS by testing the interaction of rt-PA and HAS in a logistic regression model after adjusting for age, sex, initial NIH Stroke Scale score (NIHSSS), time to randomization, systolic blood pressure, serum glucose, body temperature, and rt-PA in 616 patients treated within 3 hours of symptom onset. Outcomes evaluated included intracranial hemorrhage, modified Rankin scale (mRS) 0–1, Barthel Index (BI) of ≥ 95, Glasgow Outcome Scale (GOS) of 0–1, NIHSSS 0–1, and death at 90 days.
Results: HAS was detected on the initial CT scan in 91 (15%) of the 616 patients by an independent neuroradiologist. Significantly lower rates of mRS 0–1, BI ≥ 95, GOS of 0–1, or NIHSSS 0–1 at 90 days were observed among patients with HAS. IV rt-PA significantly increased the rates of mRS 0–1, BI ≥ 95, GOS of 0–1, or NIHSSS 0–1 at 90 days after adjusting for potential confounders without any significant modifying effect (interaction) of HAS. Among the 91 patients with HAS, rt-PA use demonstrated a trend or significance for increased adjusted rates of favorable outcomes by mRS (p = 0.04), BI (p = 0.1), GOS (p = 0.03), and NIHSSS (p = 0.01).
Conclusion: Although hyperdense artery sign is associated with poor outcome, IV recombinant tissue plasminogen activator may be beneficial in this subgroup of patients with ischemic stroke.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
File (e1.doc)
- Download
- 75.00 KB
References
1.
Gacs G, Fox AJ, Barnett HJ, Vinuela F. CT visualization of intracranial arterial thromboembolism. Stroke 1983;14:756–762.
2.
Tomsick TA, Brott TG, Olinger CP, et al. Hyperdense middle cerebral artery: incidence and quantitative significance. Neuroradiology 1989;31:312–315.
3.
Schuierer G, Huk W. The unilateral hyperdense middle cerebral artery: an early CT-sign of embolism or thrombosis. Neuroradiology 1988;30:120–122.
4.
Pressman BD, Tourje EJ, Thompson JR. An early CT sign of ischemic infarction: increased density in a cerebral artery. AJR Am J Roentgenol 1987;149:583–586.
5.
Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 1993;14:3–13.
6.
Leys D, Pruvo JP, Godefroy O, Rondepierre P, Leclerc X. Prevalence and significance of hyperdense middle cerebral artery in acute stroke. Stroke 1992;23:317–324.
7.
Tomsick T, Brott T, Barsan W, Broderick J, Haley EC, Spilker J. Thrombus localization with emergency cerebral CT. AJNR Am J Neuroradiol 1992;13:257–263.
8.
Tomsick T, Brott T, Barsan W, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. AJNR Am J Neuroradiol 1996;17:79–85.
9.
Derex L, Hermier M, Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry 2005;76:70–75.
10.
Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145–1150.
11.
Agarwal P, Kumar S, Hariharan S, et al. Hyperdense middle cerebral artery sign: can it be used to select intra-arterial versus intravenous thrombolysis in acute ischemic stroke? Cerebrovasc Dis 2004;17:182–190.
12.
Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
13.
Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999;340:1781–1787.
14.
Patel SC, Levine SR, Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA 2001;286:2830–2838.
15.
Wolfe CD, Taub NA, Woodrow EJ, Burney PG. Assessment of scales of disability and handicap for stroke patients. Stroke 1991;22:1242–1244.
16.
Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis Scott Med J 1957;2:200–215.
17.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–607.
18.
Bruno A, Biller J, Adams HP, et al. Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in acute stroke treatment (TOAST) investigators. Neurology 1999;52:280–284.
19.
Bruno A, Levine SR, Frankel MR, et al. Admission glucose level and clinical outcomes in the NINDS rt-PA stroke trial. Neurology 2002;59:669–674.
20.
Dawson S, Manktelow BN, Robinson TG, Panerai RB, Potter JF. Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischemic stroke? Stroke 2000;31:463–468.
21.
Castillo J, Davalos A, Marrugat J, Noya M. Timing for fever-related brain damage in acute ischemic stroke. Stroke 1998;29:2455–2460.
22.
Hajat C, Hajat S, Sharma P. Effects of poststroke pyrexia on stroke outcome: a meta-analysis of studies in patients. Stroke 2000;31:410–414.
23.
Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004;22:1797–1806.
24.
Bleumink GS, Schut AF, Sturkenboom MC, et al. Mortality in patients with hypertension on angiotensin-I converting enzyme (ACE)-inhibitor treatment is influenced by the ACE insertion/deletion polymorphism. Pharmacogenet Genomics 2005;15:75–81.
25.
Thakar CV, Worley S, Arrigain S, Yared JP, Paganini EP. Influence of renal dysfunction on mortality after cardiac surgery: modifying effect of preoperative renal function. Kidney Int 2005;67:1112–1119.
26.
Qureshi AI, Ali Z, Suri MF, et al. Intra-arterial third-generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 2001;49:41–48; discussion 48–50.
27.
Qureshi AI. Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004;363:804–813.
28.
Qureshi AI, Siddiqui AM, Suri MF, et al. Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study. Neurosurgery 2002;51:1319–1327.
29.
Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 2004;35:2848–2854.
Information & Authors
Information
Published In
Copyright
© 2006.
Publication History
Published online: April 24, 2006
Published in print: April 25, 2006
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Is it Possible to Predict the Outcome of Endovascular Thrombectomy for Hyperdense Middle Cerebral Artery Sign at the Time of First Admission?, Nigerian Journal of Clinical Practice, 25, 10, (1674-1680), (2022).https://doi.org/10.4103/njcp.njcp_2050_21
- Associations between early ischemic signs on non-contrast CT and time since acute ischemic stroke onset: A scoping review, European Journal of Radiology, 155, (110455), (2022).https://doi.org/10.1016/j.ejrad.2022.110455
- Management in a Patient with Stroke, Problem Based Learning Discussions in Neuroanesthesia and Neurocritical Care, (359-372), (2020).https://doi.org/10.1007/978-981-15-0458-7_26
- Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke, 50, 12, (2019).https://doi.org/10.1161/STR.0000000000000211
- Intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign: A meta‐analysis, Acta Neurologica Scandinavica, 141, 3, (193-201), (2019).https://doi.org/10.1111/ane.13177
- 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, Stroke, 49, 3, (2018).https://doi.org/10.1161/STR.0000000000000158
- Brain computed tomography using iterative reconstruction to diagnose acute middle cerebral artery stroke: usefulness in combination of narrow window setting and thin slice reconstruction, Neuroradiology, 60, 4, (373-379), (2018).https://doi.org/10.1007/s00234-018-1982-8
- Hyperdense Artery Sign, Clot Characteristics, and Response to Intravenous Thrombolysis in Han Chinese People with Acute Large Arterial Infarction, Journal of Stroke and Cerebrovascular Diseases, 25, 3, (695-701), (2016).https://doi.org/10.1016/j.jstrokecerebrovasdis.2015.11.031
- Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke, Neurology, 86, 2, (118-125), (2015)./doi/10.1212/WNL.0000000000002236
- Acute Stroke with Hyperdense Middle Cerebral Artery Sign Benefits from IV rtPA, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 35, 5, (583-587), (2014).https://doi.org/10.1017/S0317167100009367
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.